| HRA005462
(Controlled Access)
|
Immune checkpoint inhibitors have demonstrated significant clinical benefits for colorectal cancer (CRC) patients with microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR). However, the majority of CRC patients with microsatellite stable/proficient mismatch repair (MSS/pMMR) exhibit poor response to immunotherapy, and there is currently a lack of effective combination treatments. Building upon our preclinical research findings, we designed a study to investigate the potential efficacy of combining a PD-1 monoclonal antibody, sintilimab, with an HDAC inhibitor, chidamide, with or without bevacizumab, in MSS/pMMR metastatic CRC patients. We conducted an open-label, multicenter trial (NCT04724239) involving patients with MSS/pMMR metastatic CRC who had failed or were intolerant to at least two lines of standard systemic therapies. |
